Complete digital access to quality FT journalism with expert analysis from industry leaders. Pay a year upfront and save 20%.

MoonLake Immunotherapeutics has done well to develop the use of its drug Sonelokimab in the ongoing phase 3 VELA program, which is using this IL-17A/IL-17F inhibitor to target patients with ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a bid exceeding $3 billion. While MoonLake turned down the initial offer ...

NINGBO, CHINA – Media OutReach Newswire – 25 June 2025 – With the expanded implementation of the 240-hour visa-free transit policy and ongoing innovations in cultural ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff.

The Utah Department of Agriculture & Food's "Farm to School" program helps connect local agriculture producers to schools for ...

MoonLake Immunotherapeutics Price Performance. Shares of MLTX opened at $38.93 on Tuesday. MoonLake Immunotherapeutics has a 1-year low of $31.42 and a 1-year high of $58.26. The stock has a ...

Moonlake is running phase 3 studies of the nanobody in psoriatic arthritis and advancing the drug candidate toward pivotal trials in psoriasis, palmoplantar pustulosis and axial spondyloarthritis.

Investing.com -- Shares of MoonLake Immunotherapeutics soared 21.5% following reports that Merck (NSE:PROR) has engaged in discussions regarding a potential acquisition of the Swiss biotech firm ...